Is macrolide-resistant Mycoplasma pneumoniae common in children with community-acquired pneumonia?
Macrolide-resistant Mycoplasma pneumoniae (MRMP) is a growing concern in children with community-acquired pneumonia (CAP). In many regions, especially East Asia, the majority of M. pneumoniae infections in children are now resistant to macrolide antibiotics like azithromycin. This means standard first-line treatment may not work, leading to longer fevers and hospital stays.
What the research says
A 2024-2025 study from Anhui, China found that 94.4% of M. pneumoniae isolates from children with CAP were macrolide-resistant, with the A2063G mutation being most common 4. Similarly, a large retrospective study from Beijing Children's Hospital (2018-2024) reported MRMP in 96.9% of MP-positive cases, with resistance rates over 95% from 2022 onward 9. An expert consensus notes that MRMP has been increasing globally since 2000, especially in East Asia, leading to poor response to macrolides and more severe outcomes 8. While these studies focus on China, the high prevalence highlights a major clinical challenge. Other sources confirm that M. pneumoniae is a common cause of CAP in children, with prevalence varying by age and pandemic period 2, but do not directly address resistance rates.
What to ask your doctor
- If my child has Mycoplasma pneumoniae pneumonia, should we test for macrolide resistance?
- What alternative antibiotics are available if macrolides are not effective?
- How does macrolide resistance affect the expected duration of fever and hospital stay?
- Are there any local data on macrolide resistance rates in our area?
- What signs should I watch for that might indicate the infection is not responding to treatment?
This question is drawn from common patient questions about Pulmonology & Critical Care and answered using cited medical research. We do not provide individualized advice.